The National League for Nursing’s Advancing Care Excellence for Seniors (ACE.S) is committed to preparing nurses so that they can provide high quality and culturally sensitive care to older adults with dementia such as Alzheimer’s disease. According to a recent report by the John A. Hartford Foundation, one of the…
Over the last five years, Project Lifesaver International has expanded its program to new territories across the United States. The expansion was possible thanks to a Federal grant from the Bureau of Justice Assistance (BJA) under the Missing Alzheimer’s Patient Assistance program. This grant has helped fund over 205 Project Lifesaver public safety agencies since 2010.
The United States Senate Special Committee on Aging recently hosted a meeting entitled “The Fight Against Alzheimer’s Disease: Are We on Track to a Treatment by 2025?” The meeting featured the personal testimonies of Dr.Ronald Petersen from the Mayo Clinic, a top Alzheimer’s researcher and former member of the national Alzheimer’s Association; B. Smith,…
Amarantus BioSciences Holdings, Inc., a biotechnology firm advancing diagnostic and therapeutic products for orphan diseases in the areas of neurology, ophthalmology, psychiatry and regenerative medicine, recently announced that Mr. Gerald E. Commissiong, CEO and President, will be presenting at the Neurotech Investing and Partnering Conference being held at the Hotel Nikko…
Thanks to its successful drugs to address treatments for multiple sclerosis, Biogen Idec Inc has seen its position in the biopharmaceutical market increase, having quadrupled sales in just 3 years to over $100 billion dollars. The company now has new ambitions in sight and has dropped “Idec” from its name and adopted…
The Alzheimer’s Drug Discovery Foundation (ADDF) is proud to announce that it is the Official Charity Partner of the 2015 TCS New York City Marathon. The Foundation is inviting runners that were not able to secure individual spots in the 2015 TCS New York City Marathon to be part of the Runners for Alzheimer’s…
Amarantus, a biotechnology company developing diagnostics in neurology and orphan drugs in neurology, ophthalmology, psychiatry and regenerative medicine, recently announced their abstract “The LymPro® Assay: A Biomarker For Alzheimer’s Disease Using Blood Samples From Clinically Diagnosed Alzheimer’s Disease And Cognitively Intact Subjects” has been accepted for poster presentation at the …
Congressman Chaka Fattah recently met with Amarantus, a biotechnology firm specializing in discovering and developing treatments and diagnostics for Alzheimer’s disease and other degenerative brain conditions, to discuss ongoing and future neurologic research strategies. Gerald Commissiong, the CEO of Amarantus, and Robert Farrell, the CFO, had briefed Congressman…
One of the biggest challenges that research and development in the field of Alzheimer’s Disease faces is not the discovery of new treatment candidates, but the lack of funding to advance these discoveries into human testing. In addition, very few funding sources address early-phase clinical drug trials and, as a…
A researcher from the University of Oklahoma is currently developing a new therapy to address Alzheimer’s disease by using biopharmaceutical proteases. The goal is to target the harmful amyloid beta plaque that builds up in the brains of AD patients. If successful, the scientist expects this approach to be cheaper, and…
Get regular updates to your inbox.